메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner

DENVER, Aug. 27, 2025 -- Cerecin, a global biotech company focused on neurometabolism, is proud to announce its partnership with the NIHR HealthTech Research Centre (HRC) in Brain Health, joining a distinguished group of industry leaders including GE Healthcare, Novo Nordisk, Roche Diagnostics, and Camtech Innovations. The HRC, based at King's College London and the South London and Maudsley NHS Foundation Trust, is dedicated to advancing the diagnosis, care, and treatment of dementia through cutting-edge technologies. The Centre will leverage brain scanning, bloo
- 김갑성 기자
- 2025-08-27 00:04
MagMutual Transforms Operations with Appian

Appian AI-powered platform cuts policy migration time, accelerates quoting, and unifies operations. MCLEAN, Va., Aug. 26, 2025 -- Appian (NASDAQ: APPN) today announced that MagMutual has successfully transformed its operations using Appian's AI-powered platform. MagMutual is a leading provider of medical malpractice insurance, delivering comprehensive coverage to more than 40,000 healthcare providers and organizations across the United States. It partnered with Appian and Xebia to modernize its core processes and elevate the policyholder experience. The insurer faced mou
- 황정호 기자
- 2025-08-26 21:00
iNtRON Bio, files Two Patent Applications for IMPA™ Platform-Based Gene Editing Technology

[ 메디채널 김갑성 기자 ] Development of gene-editing technology for Pasteurella bacteriophages using the IMPA™ platform Establishment of an advanced platform technology based on CRISPR-Cas9 and recombination for Pasteurella Patent applications filed for core proprietary technology enabling the incorporation of diverse payloads BOSTON and SEOUL, South Korea, Aug. 26, 2025 -- iNtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a new IMPA™ gene
- 김갑성 기자
- 2025-08-26 21:00
Fosun Pharma Announces 2025 Interim Results

[ 메디채널 김갑성 기자 ] Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 ("the Reporting Period"). During the Reporting Period, Fosun Pharma continued to push forward its innovation transformation and the development and commercialization of innovative products, enhance glo
- 김갑성 기자
- 2025-08-26 20:42
Ping An Reports Stable Growth in Operating Profit Attributable to Shareholders of the Parent Company in 1H2025; Life & Health NBV Surges 39.8% YoY Interim Dividend Increases to RMB0.95 Per Share

HONG KONG and SHANGHAI, Aug. 26, 2025 -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) today announced its 2025 interim results for the six month period ended 30 June 2025. In 2025, leveraging Ping An's previous achievements, the Group continued to drive reform and innovation, making significant progress in both its strategic advancement and service enhancements. China's economy was generally stable and improved steadily despite pressure from a complex and severe external environment in
- 황정호 기자
- 2025-08-26 20:39
ZEISS showcases comprehensive workflow for full spectrum of retina care at EURETINA

At EURETINA 2025, ZEISS Medical Technology combines its diagnostic, surgical and digital technologies to support healthcare professionals in advancing retinal care: IMPROVE PATHOLOGY DETECTION: Now CE mark approved, CIRRUS® PathFinderTM AI decision support tool streamlines OCT data review; ICGA for CLARUS® 700 offers FA + ICG simultaneous capture. ACCELERATE RETINA RESEARCH: AI-ready ZEISS Research Data Platform (RDP) empowers retina specialists to transform their clinical hypotheses into measurable outcomes through smarter, more efficient research. TRANSFORM VITR
- 김갑성 기자
- 2025-08-26 20:00
앤젤어라인 테크놀로지, 2025년 상반기 실적 발표… 법률•공급망•데이터 보안 투자 확대

샌클레멘테, 캘리포니아주, 2025년 8월 26일 -- 투명 교정기 전문회사인 앤젤어라인 테크놀로지(Angelalign Technology Inc., 이하 '앤젤' 또는 '회사')(6699.HK)가 2025년 상반기 견고한 반기실적을 발표했다. 상반기 매출은 전년 동기 대비 33.1% 증가한 1억 6140만 달러를 기록했고, 매출 총이익과 조정 순이익은 각각 1억 60만 달러와 1950만 달러를 달성했다. 글로벌 투명 교정기 치료 건수는 전년 동기 대비 47.7% 증가한 약 22만 5800건을 기록했다. 교정기 출하량 증가와 치료 계획 센터 및 투명 교정기 제조 시설의 효율적인 운영이 매출, 매출 총이익, 영업 이익의 전년 동기 대비 개선을 이끌었다. 보고 기간 동안 회사의 수익성은 불확실한 관세 환경을 대비해 시행한 엄격한 비용 관리 조치의 혜택을 받았다. 회사는 일부 영업•마케팅, 임상 지원 및 고객 서비스 인력 채용을 미루는 한편, 중국 본토 외 지역에서 치료 계획 센터 및 제조 시설 운영을 지연시켰다. 앤젤은 해외에서 보다 지속 가능한 존재감을 확립하기 위해 전략적으로 여러 핵심 분야
- 김갑성 기자
- 2025-08-26 19:34
Beauty Farm Announces 2025 Interim Results

Revenue and Net Profit Reached Record High Cash-generating Capability Significantly Enhanced HONG KONG, Aug. 26, 2025 -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services providers in China, together with its subsidiaries, the "Group," is pleased to announce the Group's audited interim results for the six months ended June 30, 2024 (the "Reporting Period"). Performance Highlights: Revenue surged to RMB1,459 million, representing a YOY i
- 김갑성 기자
- 2025-08-26 19:05
Brightonix Imaging's High-Performance 'PHAROS' PET Receives FDA Clearance

SEOUL, South Korea, Aug. 26, 2025 -- Brightonix Imaging, a global leader in cutting-edge medical imaging technology, is proud to announce that its flagship product, the PHAROS PET Scanner, has received FDA clearance for commercial distribution in the United States. This milestone marks a new era of precision and efficiency in nuclear imaging and positions Brightonix Imaging at the forefront of medical innovation. The PHAROS PET is a state-of-the art clinical positron emission tomography (PET) system designed to deliver exceptional image quality, offering healthcare providers a
- 김갑성 기자
- 2025-08-26 19:00
HIRONIC Expands Presence in Indonesian Market with 'New Doublo 2.0'

SEOUL, South Korea, Aug. 26, 2025 -- HIRONIC, a leading provider of aesthetic medical devices, announced on the 19th that it has obtained certification from the Indonesian Ministry of Health (KEMENKES RI) for its flagship product, New Doublo 2.0—a state-of-the-art device combining 4th-generation High-Intensity Focused Ultrasound (HIFU) and Radiofrequency (RF) technologies in a single treatment platform. This approval officially opens the door for exports to one of Southeast Asia's fastest-growing and largest aesthetic markets. With a population of 270 million, Indonesia is the
- 김갑성 기자
- 2025-08-26 15:54

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 30일 17시 20분